跳至主要内容
临床试验/NCT00465699
NCT00465699Unknown不适用

Evaluation of Topical B12 for the Treatment of Childhood Atopic Dermatitis

Spartanburg Regional Family Medicine2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2007年4月最近更新:
适应症
相关药物

试验速览

阶段
不适用
发起方
入组人数
50
试验地点
2
主要终点
Reduction in SCORAD at 2 and 4 weeks

研究概览

简要总结

This study is being done to see in B12 applied to the skin will improve the symptoms of eczema in children compared to a placebo creme

详细描述

INTRODUCTION

Atopic dermatitis is a prevalent disease process in children, affecting up to 20% of children in the United States. Various treatment options are available to treat atopic dermatitis to include topical emollients, topical steroids, and topical calcineurin inhibitors. Each treatment option has benefits and potential risks. This study was done to determine if topical B12 could be a tolerable and efficacious alternative treatment option in this population.

METHODS: The study was conducted as a placebo-controlled, double-blind, prospective, randomized clinical trial with intraindividual left ⁄ right comparison. Parents were given 2 containers of creams and instructed to apply the Vitamin B12 cream to one side of the body and the placebo cream to the contralateral side according to the randomization scheme.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Double

入排标准

年龄范围
6 Months 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • children presenting to the Center for Family Medicine or Regional Pediatrics between the ages of 6 months and 18 years old with atopic dermatitis

排除标准

  • unwillingness of parent to consent to study protocol, pregnancy or lactation, eczema with superinfection present, known history of allergy to Vitamin B12 or components of the base cream, topical treatment with corticosteroids in the 4 weeks prior to enrollment

结局指标

主要结局

Reduction in SCORAD at 2 and 4 weeks

次要结局

未报告次要终点

研究者

发起方
Spartanburg Regional Family Medicine
申办方类型
Other

研究点 (2)

Loading locations...

相似试验